JPWO2012063820A1 - 血糖値上昇抑制剤 - Google Patents
血糖値上昇抑制剤 Download PDFInfo
- Publication number
- JPWO2012063820A1 JPWO2012063820A1 JP2012542931A JP2012542931A JPWO2012063820A1 JP WO2012063820 A1 JPWO2012063820 A1 JP WO2012063820A1 JP 2012542931 A JP2012542931 A JP 2012542931A JP 2012542931 A JP2012542931 A JP 2012542931A JP WO2012063820 A1 JPWO2012063820 A1 JP WO2012063820A1
- Authority
- JP
- Japan
- Prior art keywords
- epa
- ester
- dha
- blood glucose
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
(1)エイコサペンタエン酸(EPA)エステルまたはドコサヘキサエン酸(DHA)エステルを有効成分として含有し、食間に投与される、血糖値上昇抑制剤。
(2)食後2時間から食前1時間前までの食間に投与される、上記(1)に記載の血糖値上昇抑制剤。
(3)EPAエステルまたはDHAエステルが、EPAまたはDHAを構成脂肪酸とするトリグリセリド、またはEPAまたはDHAのC1−5アルキルエステルである、上記(1)または(2)に記載の血糖値上昇抑制剤。
(4)全脂肪酸中のEPAおよびDHAの合計含量が20重量%以上の精製魚油を有効成分とする、上記(1)〜(3)のいずれかに記載の血糖値上昇抑制剤。
(5)EPAエステルまたはDHAエステルを食間に投与することを含む、血糖値上昇抑制方法。
(6)EPAエステルまたはDHAエステルを食後2時間から食前1時間前までの食間に投与する、上記(5)に記載の血糖値上昇抑制方法。
(7)EPAエステルまたはDHAエステルが、EPAまたはDHAを構成脂肪酸とするトリグリセリド、またはEPAまたはDHAのC1−5アルキルエステルである、上記(5)または(6)に記載の血糖値上昇抑制方法。
(8)全脂肪酸中のEPAおよびDHAの合計含量が20重量%以上の精製魚油を有効成分とする、上記(5)〜(7)のいずれかに記載の血糖値上昇抑制方法。
空腹時血糖値が126mg/dL以下で、かつ糖負荷試験30分後の血糖値が130〜200mg/dLである健常人(男性4名、女性3名の計7名、43〜60歳)を対象としてOGTT後の血糖値上昇に対するEPAエステルまたはDHAエステルの効果を確認する試験を行った。
Claims (4)
- エイコサペンタエン酸のエステルまたはドコサヘキサエン酸のエステルを有効成分として含有し、食間に投与される、血糖値上昇抑制剤。
- 食後2時間〜食前1時間前までの食間に投与される、請求項1に記載の血糖値上昇抑制剤。
- エイコサペンタエン酸のエステルまたはドコサヘキサエン酸のエステルが、エイコサペンタエン酸またはドコサヘキサエン酸を構成脂肪酸とするトリグリセリド、またはエイコサペンタエン酸またはドコサヘキサエン酸のC1−5アルキルエステルである、請求項1または2に記載の血糖値上昇抑制剤。
- 全脂肪酸中のエイコサペンタエン酸およびドコサヘキサエン酸の合計含量が20重量%以上の精製魚油を有効成分とする、請求項1〜3のいずれか1項に記載の血糖値上昇抑制剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010250870 | 2010-11-09 | ||
JP2010250870 | 2010-11-09 | ||
PCT/JP2011/075723 WO2012063820A1 (ja) | 2010-11-09 | 2011-11-08 | 血糖値上昇抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2012063820A1 true JPWO2012063820A1 (ja) | 2014-05-12 |
JP5960603B2 JP5960603B2 (ja) | 2016-08-02 |
Family
ID=46050962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012542931A Expired - Fee Related JP5960603B2 (ja) | 2010-11-09 | 2011-11-08 | 血糖値上昇抑制剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130303614A1 (ja) |
EP (1) | EP2638903A4 (ja) |
JP (1) | JP5960603B2 (ja) |
CN (2) | CN103338762B (ja) |
WO (1) | WO2012063820A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
EP3797591A1 (en) | 2009-04-29 | 2021-03-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
HUE053111T2 (hu) | 2012-06-29 | 2021-06-28 | Amarin Pharmaceuticals Ie Ltd | Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US11382980B2 (en) | 2013-10-08 | 2022-07-12 | Taiyo Kagaku Co., Ltd. | Oil/fat composition containing polyunsaturated fatty acid |
JP6393501B2 (ja) * | 2014-04-03 | 2018-09-19 | 太陽化学株式会社 | 多価不飽和脂肪酸含有油脂の風味改善剤 |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
TWI791738B (zh) * | 2018-01-12 | 2023-02-11 | 日商明治股份有限公司 | Glp-1分泌促進用營養組成物 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404483D0 (en) | 1994-03-08 | 1994-04-20 | Norsk Hydro As | Refining marine oil compositions |
JP4139544B2 (ja) * | 2000-03-06 | 2008-08-27 | 花王株式会社 | 血糖値低下剤 |
CN1180785C (zh) * | 2001-09-30 | 2004-12-22 | 中国药品生物制品检定所 | 海狗油作为制备治糖尿病药的应用 |
BRPI0408006A (pt) * | 2003-03-05 | 2006-02-14 | Solvay Pharm Gmbh | uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos |
JP4757190B2 (ja) | 2004-03-01 | 2011-08-24 | ファルマフロンティア株式会社 | 血糖値の低下に供される医薬組成物 |
AU2006269568A1 (en) * | 2005-07-07 | 2007-01-18 | Ocean Nutrition Canada Ltd. | Food articles with delivery devices and methods for the preparation thereof |
DK2006389T3 (en) | 2006-04-13 | 2017-08-28 | Nippon Suisan Kaisha Ltd | Process for preparing concentrated polyunsaturated fatty acid oil |
-
2011
- 2011-11-08 CN CN201180053961.3A patent/CN103338762B/zh not_active Expired - Fee Related
- 2011-11-08 EP EP11839308.1A patent/EP2638903A4/en not_active Withdrawn
- 2011-11-08 US US13/884,089 patent/US20130303614A1/en not_active Abandoned
- 2011-11-08 WO PCT/JP2011/075723 patent/WO2012063820A1/ja active Application Filing
- 2011-11-08 CN CN201510115370.4A patent/CN104814950A/zh active Pending
- 2011-11-08 JP JP2012542931A patent/JP5960603B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103338762A (zh) | 2013-10-02 |
EP2638903A1 (en) | 2013-09-18 |
CN104814950A (zh) | 2015-08-05 |
US20130303614A1 (en) | 2013-11-14 |
WO2012063820A1 (ja) | 2012-05-18 |
JP5960603B2 (ja) | 2016-08-02 |
EP2638903A4 (en) | 2013-12-04 |
CN103338762B (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5960603B2 (ja) | 血糖値上昇抑制剤 | |
Donadio et al. | The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy | |
US20190183839A1 (en) | Methods of treating pediatric metabolic syndrome | |
JP2009051732A (ja) | Pparリガンド活性を有する組成物 | |
CN106470675A (zh) | 严重高甘油三酯血症的治疗 | |
JP2017200910A (ja) | 血糖値上昇抑制剤 | |
EP2682116A1 (en) | Metabolic syndrome ameliorating agent | |
JP5718293B2 (ja) | Gip上昇抑制剤 | |
JP2006306813A (ja) | 肥満細胞増殖抑制剤 | |
JP4139544B2 (ja) | 血糖値低下剤 | |
JP2009019005A (ja) | 脂肪分解促進剤 | |
JP2011063557A (ja) | Ppar活性化剤 | |
JP5576699B2 (ja) | Gip上昇抑制剤 | |
JP4634065B2 (ja) | アディポネクチン低下抑制剤 | |
JP2004210652A (ja) | 糖尿病患者における脂質代謝改善剤 | |
WO2013005834A1 (ja) | 高純度epaを含有する抗肥満剤 | |
JP2008179609A (ja) | 血中アディポネクチン増加剤 | |
JP2013063937A (ja) | Gip上昇抑制剤 | |
JP6053695B2 (ja) | 食欲抑制剤 | |
WO2022210856A1 (ja) | 睡眠の質を改善するための組成物 | |
JP2015205846A (ja) | レプチン分泌促進剤 | |
JP2019127470A (ja) | リウマチ性疾患の治療用または予防用組成物 | |
CA2538494C (en) | Composition for modulating blood parameters | |
JP2010241832A (ja) | アディポネクチン低下抑制剤 | |
Frøyland et al. | Risk assessment of “other substances”–eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150707 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150902 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151210 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160226 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160226 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160421 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160609 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160623 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5960603 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |